Blood Based Biomarkers Market Growth & Trends
The global blood based biomarkers market size is expected to reach USD 11.58 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.2% from 2025 to 2030. Rise in the prevalence of chronic diseases along with expanding research and funding drives the blood based biomarkers industry. As the demand for non-invasive diagnostic tools increases, governments, private sectors, and research institutions are prioritizing the funding of studies focused on developing and validating blood-based biomarkers for a wide range of diseases, including cancer, cardiovascular disorders, and neurological conditions. This increased investment enables innovative breakthroughs, enhances the accuracy and reliability of biomarkers, and accelerates the commercialization of new diagnostic tests. Additionally, the growing collaboration between academic institutions, biotechnology companies, and healthcare providers fosters the development of novel technologies, further driving market expansion and improving patient care outcomes.
Technological advancements and launches significantly drives the market, as innovations in high-throughput screening, next-generation sequencing (NGS), and mass spectrometry enhance the sensitivity and precision of biomarker detection. These advancements enable the identification of previously undetectable biomarkers, expanding the range of diseases that can be diagnosed through blood tests. Additionally, the development of microfluidic devices and wearable sensors allows for faster, more cost-effective, and less invasive testing. As technology continues to improve, it enhances the scalability and clinical applicability of blood-based biomarker assays, making them more accessible and valuable for early disease detection, personalized medicine, and monitoring treatment efficacy, thus fueling market growth.
The announcement of Exact Sciences Corp.'s promising performance data for its blood-based colorectal cancer screening test highlights a major advancement for the blood-based biomarker sector: the increasing effectiveness of early detection tests. With sensitivity rates of 88.3% for CRC and 31.2% for advanced precancerous lesions, coupled with a high specificity of 90.1%, the success of such tests reinforces the growing potential of blood-based diagnostics in cancer screening. As more innovative blood-based tests demonstrate high accuracy and reliability, the demand for these non-invasive, early detection solutions is expected to surge, driving further advancements in the market. This progress encourages investment, enhances patient outcomes, and strengthens the adoption of blood-based biomarkers across multiple cancer types.
Blood Based Biomarkers Market Report Highlights
- In 2024, the genetic biomarkers segment was the largest revenue-generating sector of the blood based biomarkers industry. This is attributed to the growing adoption of genetic biomarkers in blood-based diagnostics is driven by advancements in comprehensive genomic profiling.
- Cancer was the most dominating segment in 2024 due to the consistent research, extensive collaborations among industry leaders to develop blood-based biomarkers for early diagnosis. Increasing cases of cancer and thereby rise in the demand for non invasive methods for diagnosis fuel the segment’s growth.
- Next-Generation Sequencing (NGS) segment dominated the market in 2024 due to the advancements in the technology and rising focus of several key players to develop innovative blood-based biomarkers.
- Hospitals and Clinics segment held the largest share of the end use segment in 2024. This dominance is attributed to the rising prevalence of chronic diseases. As hospitals are center to all the advanced diagnostic services, such as blood-based biomarker testing, patients entrust the established hospitals thus, fueling market growth.
- The North American region is set to reign the global market in the year 2024. The rising implementation of advanced diagnostic tools, increasing wareness, presence of industry leaders in the region and regulatory approvals are anticipated to contribute to the market growth
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Type
- 1.2.2. Application
- 1.2.3. Technology
- 1.2.4. End Use
- 1.2.5. Regional scope
- 1.2.6. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.4.5.2. Data for primary interviews in Europe
- 1.4.5.3. Data for primary interviews in Asia Pacific
- 1.4.5.4. Data for primary interviews in Latin America
- 1.4.5.5. Data for Primary interviews in MEA
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type, application, technology, and end-use outlook
- 2.2.2. Regional outlook
- 2.3. Competitive Insights
- Chapter 3. Blood Based Biomarkers Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising prevalence of chronic diseases
- 3.2.1.2. Advancements in biomarker technology
- 3.2.1.3. Expanding research and funding support
- 3.2.2. Market restraint analysis
- 3.2.2.1. High development and validation costs
- 3.2.2.2. Lack of reimbursement policies for biomarker treatment
- 3.3. Blood Based Biomarkers Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Social landscape
- 3.3.2.5. Environmental landscape
- Chapter 4. Blood Based Biomarkers Market: Type Estimates & Trend Analysis
- 4.1. Global Blood Based Biomarkers Market: Type Dashboard
- 4.2. Global Blood Based Biomarkers Market: Type Movement Analysis
- 4.3. Global Blood Based Biomarkers Market by Type, Revenue
- 4.4. Genetic Biomarkers
- 4.4.1. Genetic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
- 4.5. Protein Biomarkers
- 4.5.1. Protein Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
- 4.6. Metabolic Biomarkers
- 4.6.1. Metabolic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
- 4.7. Cell-Based Biomarkers
- 4.7.1. Cell-Based Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
- 4.8. Epigenetic Biomarkers
- 4.8.1. Epigenetic Biomarkers market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 5. Blood Based Biomarkers Market: Application Estimates & Trend Analysis
- 5.1. Global Blood Based Biomarkers Market: Application Dashboard
- 5.2. Global Blood Based Biomarkers Market: Application Movement Analysis
- 5.3. Global Blood Based Biomarkers Market by Application , Revenue
- 5.4. Cancer
- 5.4.1. Cancer market estimates and forecasts 2018 to 2030 (USD Billion)
- 5.5. Cardiovascular Diseases
- 5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Billion)
- 5.6. Neurological Diseases
- 5.6.1. Neurological diseases market estimates and forecasts 2018 to 2030 (USD Billion)
- 5.7. Immunological Diseases
- 5.7.1. Immunological diseases market estimates and forecasts 2018 to 2030 (USD Billion)
- 5.8. Others
- 5.8.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 6. Blood Based Biomarkers Market: End Use Estimates & Trend Analysis
- 6.1. Global Blood Based Biomarkers Market: End Use Dashboard
- 6.2. Global Blood Based Biomarkers Market: End Use Movement Analysis
- 6.3. Global Blood Based Biomarkers Market by End Use, Revenue
- 6.4. Hospitals & Clinics
- 6.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Billion)
- 6.5. Diagnostic Laboratories
- 6.5.1. Diagnostic laboratories market estimates and forecasts 2018 to 2030 (USD Billion)
- 6.6. Research & Academic Institutes
- 6.6.1. 6.6. Research & academic institutes market estimates and forecasts 2018 to 2030 (USD Billion)
- 6.7. Others
- 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 7. Blood Based Biomarkers Market: Regional Estimates & Trend Analysis by Type, Application, Technology, and End Use
- 7.1. Regional Dashboard
- 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 7.3. North America
- 7.3.1. U.S.
- 7.3.1.1. Key country dynamics
- 7.3.1.2. Regulatory framework/ reimbursement structure
- 7.3.1.3. Competitive scenario
- 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.3.2. Canada
- 7.3.2.1. Key country dynamics
- 7.3.2.2. Regulatory framework/ reimbursement structure
- 7.3.2.3. Competitive scenario
- 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.3.3. Mexico
- 7.3.3.1. Key country dynamics
- 7.3.3.2. Regulatory framework/ reimbursement structure
- 7.3.3.3. Competitive scenario
- 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Key country dynamics
- 7.4.1.2. Regulatory framework/ reimbursement structure
- 7.4.1.3. Competitive scenario
- 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.4.2. Germany
- 7.4.2.1. Key country dynamics
- 7.4.2.2. Regulatory framework/ reimbursement structure
- 7.4.2.3. Competitive scenario
- 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.4.3. France
- 7.4.3.1. Key country dynamics
- 7.4.3.2. Regulatory framework/ reimbursement structure
- 7.4.3.3. Competitive scenario
- 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.4.4. Italy
- 7.4.4.1. Key country dynamics
- 7.4.4.2. Regulatory framework/ reimbursement structure
- 7.4.4.3. Competitive scenario
- 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.4.5. Spain
- 7.4.5.1. Key country dynamics
- 7.4.5.2. Regulatory framework/ reimbursement structure
- 7.4.5.3. Competitive scenario
- 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.4.6. Norway
- 7.4.6.1. Key country dynamics
- 7.4.6.2. Regulatory framework/ reimbursement structure
- 7.4.6.3. Competitive scenario
- 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.4.7. Sweden
- 7.4.7.1. Key country dynamics
- 7.4.7.2. Regulatory framework/ reimbursement structure
- 7.4.7.3. Competitive scenario
- 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.4.8. Denmark
- 7.4.8.1. Key country dynamics
- 7.4.8.2. Regulatory framework/ reimbursement structure
- 7.4.8.3. Competitive scenario
- 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Key country dynamics
- 7.5.1.2. Regulatory framework/ reimbursement structure
- 7.5.1.3. Competitive scenario
- 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.5.2. China
- 7.5.2.1. Key country dynamics
- 7.5.2.2. Regulatory framework/ reimbursement structure
- 7.5.2.3. Competitive scenario
- 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.5.3. India
- 7.5.3.1. Key country dynamics
- 7.5.3.2. Regulatory framework/ reimbursement structure
- 7.5.3.3. Competitive scenario
- 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.5.4. Australia
- 7.5.4.1. Key country dynamics
- 7.5.4.2. Regulatory framework/ reimbursement structure
- 7.5.4.3. Competitive scenario
- 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.5.5. South Korea
- 7.5.5.1. Key country dynamics
- 7.5.5.2. Regulatory framework/ reimbursement structure
- 7.5.5.3. Competitive scenario
- 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.5.6. Thailand
- 7.5.6.1. Key country dynamics
- 7.5.6.2. Regulatory framework/ reimbursement structure
- 7.5.6.3. Competitive scenario
- 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Key country dynamics
- 7.6.1.2. Regulatory framework/ reimbursement structure
- 7.6.1.3. Competitive scenario
- 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.6.2. Argentina
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Regulatory framework/ reimbursement structure
- 7.6.2.3. Competitive scenario
- 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Regulatory framework/ reimbursement structure
- 7.7.1.3. Competitive scenario
- 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Regulatory framework/ reimbursement structure
- 7.7.2.3. Competitive scenario
- 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.7.3. UAE
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Regulatory framework/ reimbursement structure
- 7.7.3.3. Competitive scenario
- 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
- 7.7.4. Kuwait
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Regulatory framework/ reimbursement structure
- 7.7.4.3. Competitive scenario
- 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)
- Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2024
- 8.3.4. Abbott
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. BIOMÉRIEUX
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. F. Hoffmann-La Roche Ltd.
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Siemens Healthineers AG
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Thermo Fisher Scientific, Inc.
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Bio-Rad Laboratories, Inc
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Cleveland Diagnostics, Inc.
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Sysmex Corporation
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Product benchmarking
- 8.3.11.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook